1ISG-003 Cost saving in antiretroviral therapy through breaking fixed-dose combination and switch to generic formulations

BACKGROUND: The commercialisation of fixed-dose combination meant an improvement in antiretroviral therapy (ART). With generics we have the opportunity to maintain the therapy at a lower cost, but we complicate the dosage regimen again. PURPOSE: To assess the effect in costs of a two-pill, generic-b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Molina, M Bullejos, Delgado, C Romero, Aller, T Virgos, Gomez, G Calzado, Eguior, N Yurrebaso, Campos, M Perez, Ponsjoan, S Gonzalez, Casariego, J Nazco
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 1: Introductory statements and governance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535606/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados